Identifying biomarkers for autoimmune diseases affecting the nervous system

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on autoimmune diseases of the nervous system, including conditions like Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis. The researchers aim to recruit patients diagnosed with these diseases to discover biomarkers that can aid in early diagnosis, disease monitoring, and personalized treatment. By utilizing advanced techniques such as proteomics and metabolomics, the study seeks to enhance understanding of these complex conditions and improve patient outcomes. The study will also include sex and age-matched healthy individuals for comparison.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical diagnosis with autoinflammatory diseases of the nervous system, including: Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy(IIM), multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), ect al.
* sex and age-matched healthy individuals

Exclusion Criteria:

* Known history of primary immunodeficiency (innate or acquired).
* Patients with severe central nervous system, pulmonary, or other systemic infections.
* Patients with secondary central nervous system demyelinating lesions, such as those caused by vasculitis, systemic lupus erythematosus, and Sjögren's syndrome.
* Patients with vascular (including hemorrhagic and ischemic), hereditary metabolic, neoplastic, or toxic diseases.
* Pregnant or lactating women.

Where it's running

• Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, China Recruiting

Study contacts

• Principal investigator: Dai-shi Tian, MD — Tongji Hospital
• Study coordinator: Luo-qi Zhou, MD
• Email: zhouluoqi@tjh.tjmu.edu.cn
• Phone: 86-27-83663337

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using CT103A cells to treat autoimmune diseases of the nervous system

  This study is testing if a new treatment using CT103A cells can help people with certain autoimmune diseases affecting the nervous system feel better.

  Recruiting Early Phase 1 Tongji Hospital · Wuhan, Hubei · NCT04561557

• Universal CD19/BCMA CAR T-cell therapy for relapsed or refractory neurological autoimmune diseases

  This will test whether a single infusion of universal CD19/BCMA CAR T-cells given after chemotherapy helps adults with relapsed or refractory neurological autoimmune diseases who have CD19- or BCMA-positive B cells.

  Recruiting Early Phase 1 Tianjin Huanhu Hospital · Tianjin · NCT06939166

• Music-4-MS: A 12-week music-based program to support thinking skills in people with MS

  A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.

  Recruiting University of Texas at Austin · Austin, Texas · NCT07759115

• Pregnant Women with Neuroimmune Diseases: A long-term follow-up study

  This study follows women with neuroimmune diseases and healthy controls through pregnancy and up to ten years to see how pregnancy affects disease activity and outcomes for both mother and baby.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT07653984

• BAFF‑R CAR T‑cell treatment for refractory neuroimmune diseases

  This trial will try personalized BAFF‑R CAR T cells to reduce disease activity in people with hard‑to‑treat conditions such as CIDP, NMOSD, myasthenia gravis, and inflammatory myopathies.

  Recruiting Phase 1/2 Tianjin Medical University General Hospital · Tianjin, Tianjin Municipality · NCT07022197

• Treatment of generalized myasthenia gravis with a new CAR-T therapy

  This study is testing a new CAR-T therapy to see if it can safely help adults with generalized myasthenia gravis feel better.

  Recruiting at 14 sites Phase 1 Gilead Sciences · Los Angeles, California and 13 other locations · NCT06626919

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.